Found 25 clinical trials
A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression
Pembrolizumab is approved drug for the treatment of NSCLC. It works with your immune system to help fight certain cancers. The study is split into two portions - dose escalation and randomization.
- 0 views
- 19 Feb, 2024
- 39 locations
Dose Escalation of DF6002 in Patients With Advanced Solid Tumors and Expansion in Selected Indications
This study is a Phase 1/2, open-label, dose-escalation study with a consecutive parallel-group efficacy expansion study, designed to determine the safety, tolerability, PK, pharmacodynamics, and preliminary anti-tumor activity of DF6002 as monotherapy and in combination with pembrolizumab.
- 0 views
- 19 Feb, 2024
- 1 location
Longitudinal Immune-phenotyping of HCC Following MK-3475
The study comprises a main study of pembro-treated HCC patients and a sub-study of untreated HCC patients. In the main study, patients will be treated with pembrolizumab as neoadjuvant treatment approximately 4 weeks prior scheduled surgery. Adjuvant treatment with pembrolizumab with commence at approximately 4 weeks post-surgery for up to …
- 0 views
- 19 Feb, 2024
- 1 location
Bioequivalence and the Tolerability and Antitumor Activity of Selinexor Combination Treatment
During the Combination Therapy Period, the safety and preliminary anti-tumor activity of selinexor in combination with docetaxel (for patients with NSCLC) or pembrolizumab (for patients with CRC) will be evaluated.
- 0 views
- 19 Feb, 2024
- 3 locations
A First-in-human Study Using BDC-1001 in Advanced and HER2-Expressing Solid Tumors
A first-in-human study using BDC-1001 in HER2 expressing advanced malignancies
- 0 views
- 19 Feb, 2024
- 7 locations